ClinicalTrials.gg
CompletedNCT03928600Updated Jan 23, 2023

Labor Induction With a Combined Method (Pharmacologic and Mechanical): Randomized Controlled Trial

An interventional study of Cervical Foley combined with Misoprostol and Dinoprostone 10mg insert OR in Labor, Induced and Cervical Ripening, sponsored by Centro Hospitalar De São João, E.P.E.. Completed at 1 site in Portugal. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-23.

Sponsored by Centro Hospitalar De São João, E.P.E. · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Feb 2018, registered Mar 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

Labor induction is a common pregnancy procedure worldwide. Both mechanical and pharmacologic agents are used for induction of labor. These agents reduce the incidence of cesarean delivery in women undergoing induction.

Opposite to old studies of cervical ripening, some recent studies have shown promise in reducing labor time and risk of cesarean delivery with combination methods. The effectiveness of this procedure is of major clinical importance and has a large impact in our quotidian practice.

The objective is to compare the effectiveness of a combined new method to current guidelines of our department

Read the detailed description

We designed a randomized trial that will compare two groups: misoprostol-cervical Foley simultaneously and the current department guidelines (misoprostol alone/dinoprostone alone).

Inclusion criteria: full-term (≥ 37 weeks of gestation), singleton, vertex-

02

Conditions studied

  • Labor, Induced
  • Cervical Ripening

Keywords

  • induction of labor
  • cervical ripening
  • combined methods
03

In context

Lead sponsor

Centro Hospitalar De São João, E.P.E. is the lead sponsor of 12 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • full-term (≥ 37 weeks of gestation)
  • singleton
  • vertex-presenting gestations
  • with no to vaginal delivery
  • intact membranes
  • Bishop score \< 7 and cervical dilation ≤2 cm

Exclusion criteria

Exclusion Criteria:

  • for misoprostol
  • history of previous caesarean
  • rupture of membranes,
  • fetal or maternal morbidities (fetal major abnormalities, FIGO definition of pathological CTG, HELLP syndrome, preeclampsia or hypertension with severe features, fetal growth restriction)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
140 participants (actual)

Study arms

  • Experimental
    Combined method induction group

    * 25 micrograms misoprostol vaginal applied placed along with cervical Foley (team will repeat misoprostol application each 4 hours till 6 doses of misoprostol) * After 4 hours of last misoprostol initiate oxytocin. * Cervical Foley will be removed after 12h of placement or when fails out.

    Combination Product: Cervical Foley combined with Misoprostol

  • Placebo comparator
    Current department guidelines group

    * Following current department guidelines, as usual, with the method considered more suitable. * If they opted for vaginal misoprostol, team will insert 25micrograms, repeat application 4/4h, until 150micrograms, after last misoprostol, wait 4 hours before initiating oxytocin. * If option is vaginal dinoprostone the insert of 10mg is removed after 24h in place.

    Drug: Dinoprostone 10mg insert OR · Drug: Misoprostol

Interventions

  • Combination productCervical Foley combined with Misoprostol

    Placement of cervical Foley catheter along with application of vaginal misoprostol 25ug that will be repeated 4/4h until 150ug

  • DrugDinoprostone 10mg insert OR

    Application for 24h of Dinoprostone 10mg insert

  • DrugMisoprostol

    Application of vaginal misoprostol 25ug 4/4h until 150ug

06

What researchers measure

Primary outcomes

  1. Time to delivery

    Time to delivery

    Time frame: 3 days

Secondary outcomes

  1. cesarean delivery rate

    cesarean delivery rate

    Time frame: 3 days

  2. time to active labor

    defined as dilation of 6 cm or greater

    Time frame: 3 days

  3. rate of delivery within 12 hours

    rate of delivery within 12 hours

    Time frame: 12 hours

  4. rate of delivery within 24 hours

    rate of delivery within 24 hours

    Time frame: 24 hours

  5. mean of maternal length of stay

    induction to discharge

    Time frame: average 3 days

  6. indication for cesarean delivery

    indication for cesarean delivery

    Time frame: 3 days

  7. composite maternal morbidity outcome

    third- or fourth-degree perineal laceration, blood transfusion, chorioamnionitis, endometritis, wound infection, venous thromboembolism, hysterectomy, intensive care unit admission or death.

    Time frame: 6 weeks

  8. composite of neonatal morbidities

    SDR, neonatal sepsis, blood transfusion, encephalopathy hypoxic-ischemic, intraventricular hemorrhage of grade III/IV

    Time frame: 30 days

07

Study locations

1 site
  • Centro Hospitalar São João
    Porto, 4100, Portugal
08

References and documents

Individual participant data

Plan to share: Yes — Study Protocol, Informed Consent Form, Statistical Analysis Plan

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: no ending

Access criteria: Researchers who provide a methodologically sound proposal.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in Jan 2020, 23 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2019
First posted
Apr 26, 2019
StartActual
Feb 1, 2018
Primary completionActual
Jan 31, 2020
CompletionActual
Feb 29, 2020
Last update
Jan 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03928600
Lead sponsor
Centro Hospitalar De São João, E.P.E.
Responsible party
Rita Polónia Valente (Principal Investigator, Centro Hospitalar De São João, E.P.E.) — Principal investigator
First posted
Apr 26, 2019
Start date
Feb 1, 2018
Primary completion
Jan 31, 2020
Completion
Feb 29, 2020
Last update
Jan 23, 2023

Study contacts

Rita P Valente, MD
principal investigator · Centro Hospitalar São João, Porto

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion